Real-World Treatment Patterns and Outcomes Associated with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Patients Treated with Immuno-Oncologic Agents in a US Community Oncology Setting from 2015 to 2019
Author(s)
Shukla S1, Stafkey-Mailey D2, Lunacsek O2, Roy-Ghanta S3, Ballas M3, Bell K3
1GlaxoSmithKline, Paramus, NJ, USA, 2Xcenda, Palm Harbor, FL, USA, 3GlaxoSmithKline, Collegeville, PA, USA
Presentation Documents
OBJECTIVES: Anti–PD-1 trials have shown improved outcomes with immuno-oncologic (I-O) agents nivolumab and pembrolizumab for R/M HNSCC. However, identification of predictors of response and optimal treatment patterns are required. These analyses evaluated real-world treatment patterns and survival outcomes in I-O-treated patients in US community oncology settings. METHODS: Data from the International Oncology Network Electronic Medical Record were reviewed for patients with HNSCC diagnosis who initiated treatment with an I-O agent between September 2015 and September 2019. I-O treatment characteristics were assessed descriptively and overall survival (OS) and progression-free survival (PFS) by line of therapy via Kaplan–Meier analyses. RESULTS: In 143 eligible patients, the only I-O agents used were nivolumab (N=68, 47.6%) and pembrolizumab (N=75, 52.4%). The mean time from R/M diagnosis to I-O agent initiation was 9.8 months (±19.2) for these patients. Most patients (96.5%) received I-O as monotherapy; pembrolizumab was given in combination with platinum chemotherapy in 6.7% of patients. Mean treatment duration was 6.7 (±8.1) and 6.8 (±7.8) months for nivolumab and pembrolizumab, respectively. In total, 12.6% of patients were re-challenged with an I-O agent. Disease progression was the most common reason for discontinuation for both nivolumab (36.8%) and pembrolizumab (36.0%); 14.7% and 8.0% of patients receiving nivolumab and pembrolizumab, respectively, were discontinued due to death. Median PFS was 3.4 months (95% confidence interval [CI]: 2.8, 4.4) and median OS was 11.5 months (95% CI: 8.5, 14.8); 55.2% of patients died during the follow-up period. CONCLUSIONS: Data from these analyses are similar to previous clinical trial data that demonstrated improved PFS and OS (2.0 months and 7.5–8.4 months, respectively) with I-O agents in R/M HNSCC. Optimal treatment patterns remain to be defined and additional analyses are needed to identify patient subpopulations in R/M HNSCC who benefit from I-O regimens. Study funding: GlaxoSmithKline (GSK Study 208309).
Conference/Value in Health Info
2021-05, ISPOR 2021, Montreal, Canada
Value in Health, Volume 24, Issue 5, S1 (May 2021)
Code
PCN229
Topic
Clinical Outcomes, Health Service Delivery & Process of Care, Real World Data & Information Systems
Topic Subcategory
Clinical Outcomes Assessment, Distributed Data & Research Networks, Treatment Patterns and Guidelines
Disease
Oncology